Pre-made Duvortuxizumab benchmark antibody ( Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Duvortuxizumab benchmark antibody (Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-161-1mg	1mg	Inquiry
GMP-Bios-ab-161-10mg	10mg	Inquiry
GMP-Bios-ab-161-100mg	100mg	Inquiry
GMP-Bios-ab-161-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Duvortuxizumab
Target	CD19;CD3E
Format	Bispecific scFv with Crossover
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2016
Year Recommended	2017
Companies	Janssen Biotech;MacroGenics
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma
Development Tech	Dual-Affinity Re-Targeting Technology